Cited by 1,124Diabetes Treatment and ManagementPeptidase Inhibition and AnalysisPancreatic function and diabetes

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T J, McIntosh, C H, Pederson, R A·1995·Endocrinology

Open this paper in CoChat — free account

Abstract

The combined actions of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) may fully account for the incretin effect. These hormones are released from the small intestine in response to oral glucose and stimulate insulin release. Recently, evidence has been provided demonstrating the degradation of GIP-(1-42) and GLP-1-(7-36)NH2 by the serum enzyme dipeptidyl peptidase IV (DPP IV) into the biologically inactive products GIP-(3-42) and GLP-1-(9-36)NH2. The objective of the current investigation was to develop a method to monitor the degradation of these hormones in vivo. Synthetic peptides were radiolabeled and purified by HPLC. Subsequent degradation of the peptides under various conditions was then monitored by further HPLC analysis. Incubation of [125I]GIP-(1-42) or [125I]GLP-1-(7-36)NH2 with Wistar rat serum or purified DPP IV resulted in the major N-terminal-truncated products [125I]GIP-(3-42) and [125I]GLP-1-(9-36)NH2. These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. When the labeled peptides were infused into rats at hormone levels within the physiological range, over 50% was metabolized to the truncated forms within 2 min. These products were absent when the tracers were infused into DPP IV-deficient animals. It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo. As the N-terminal-truncated products of the DPP IV cleavage may not be distinguished from the biologically active hormone by currently employed assays, reports of circulating hormone levels should be reconsidered. The method described in this manuscript may be useful for investigating the durations of action of GIP and tGLP-1 in normal and pathophysiological conditions.

Integrity signals

Registry

Crossref · 10.1210/endo.136.8.7628397

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)
Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 591
Proline-Dependent Structural and Biological Properties of Peptides and Proteins
Yaron, A., Naider, F. R., & Scharpé, S. (1993) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239309082572 · Cited by 551
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-?-naphthylamide
Hopsu-Havu, V. K., & Glenner, G. G. (1966) · Histochemistry and Cell Biology · doi:10.1007/bf00577838 · Cited by 437
Entero-Insular Axis
Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371

Show all 36 references

Sorted by citations

Items 301–400 of 997

Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 74
Dipeptide Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: Determinants of Potency and in Vivo Efficacy and Safety
Connolly, B. A., Sanford, D. G., Chiluwal, A. K., Healey, S. E., Peters, D. E., DiMare, M. T., Wu, W., Liu, Y., Maw, H. H., Zhou, Y., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800390n · Cited by 72
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
Biftu, T., Scapin, G., Singh, S. B., Feng, D., Becker, J. W., Eiermann, G. J., He, H., Lyons, K., Patel, S. B., Petrov, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.095 · Cited by 71
Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP
O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., & Flatt, P. R. (2002) · Diabetologia · doi:10.1007/s00125-002-0894-6 · Cited by 72
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Joy, S. V., Rodgers, P. T., & Scates, A. C. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e245 · Cited by 72
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 74
Plasticity of the β cell insulin secretory competence: preparing the pancreatic β cell for the next meal
Hinke, S. A., Hellemans, K., & Schuit, F. C. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.064881 · Cited by 70
Influence of Sleeve Gastrectomy on Several Experimental Models of Obesity: Metabolic and Hormonal Implications
Sabench, F., Gonzàlez, M. H., Rovira, A. F., Blasco, S. B., Morandeira-Rivas, A., & Déjardin, D. D. C. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9351-4 · Cited by 70
Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice
Kumar, M., Hunag, Y. P., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302836 · Cited by 69
GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Deacon, C. F., Plamboeck, A., ROSENKILDE, M. M., de Heer, J., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00577.2005 · Cited by 70
Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
Pospisilik, J. A., Hinke, S. A., Pederson, R. A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U. F., McIntosh, C. H. S., & Demuth, H. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00170-1 · Cited by 70
Self-citation
Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
CHILTON, R. J., Wyatt, J., Nandish, S., OLIVEROS, R. A., & Lujan, M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.004 · Cited by 68
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Nishizawa, M., Moore, M. C., Shiota, M., Gustavson, S. M., Snead, W. L., Neal, D. W., & Cherrington, A. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00503.2002 · Cited by 69
Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Luo, G., Liu, H., & Lu, H. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12777 · Cited by 70
Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease
Steven, S., Münzel, T. F., & Daiber, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818185 · Cited by 68
Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut
Fujita, Y., Asadi, A., Yang, G. K., Kwok, Y. N., & Kieffer, T. J. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00024.2010 · Cited by 64
Self-citation
PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice
Lee, S., Youn, Y. S., Lee, S.-H., Byun, Y., & Lee, K. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0234-3 · Cited by 66
Comparative Analysis of Binding Kinetics and Thermodynamics of Dipeptidyl Peptidase-4 Inhibitors and Their Relationship to Structure
Schnapp, G., Klein, T., Hoevels, Y., Bakker, R. A., & Nar, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00475 · Cited by 66
Rigidity and Flexibility of Dipeptidyl Peptidase IV: Crystal Structures of and Docking Experiments with DPIV
Engel, M., Hoffmann, T., Manhart, S., Heiser, U. F., Chambre, S., Huber, R., Demuth, H., & Bode, W. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.11.014 · Cited by 65
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 70
NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.
O'Harte, F. P. M., Mooney, M. H., & Flatt, P. R. (1999) · Diabetes · doi:10.2337/diabetes.48.4.758 · Cited by 65
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
Gallwitz, B., Ropeter, T., Morys‐Wortmann, C., Mentlein, R., Siegel, E. G., & Schmidt, W. E. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00095-6 · Cited by 68
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
Hernandez, N. S., & Schmidt, H. D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.026 · Cited by 66
Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
Barrera, J. G., D’Alessio, D. A., Drucker, D. J., Woods, S. C., & Seeley, R. J. (2009) · Diabetes · doi:10.2337/db09-0281 · Cited by 63
The physiological role of the brain GLP-1 system in stress
Holt, M. K., & Trapp, S. (2016) · Cogent Biology · doi:10.1080/23312025.2016.1229086 · Cited by 64
Dipeptidyl Peptidase IV Inhibition Improves Impaired Glucose Tolerance in High-Fat Diet-Fed Rats: Study Using a Fischer 344 Rat Substrain Deficient in Its Enzyme Activity
Mitani, H., Takimoto, M., Hughes, T. E., & Kimura, M. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.88.442 · Cited by 64
Effect of Glucagon-Like Peptide 1 on Non–Insulin-Mediated Glucose Uptake in the Elderly Patient With Diabetes
Meneilly, G. S., McIntosh, C. H. S., Pederson, R. A., Habener, J. F., Gingerich, R. L., Egan, J. M., Finegood, D. T., & Elahi, D. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1951 · Cited by 63
Self-citation
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice
Suarez‐Pinzon, W. L., Cembrowski, G. S., & Rabinovitch, A. (2009) · Diabetologia · doi:10.1007/s00125-009-1390-z · Cited by 62
Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation
Punjabi, M., Arnold, M., Geary, N., Langhans, W., & Pacheco‐López, G. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.038 · Cited by 62
Discovery of Potent and Selective Dipeptidyl Peptidase IV Inhibitors Derived from β-Aminoamides Bearing Subsituted Triazolopiperazines
Kim, D., Kowalchick, J. E., Brockunier, L. L., Parmee, E. R., Eiermann, G. J., Fisher, M. H., He, H., Leiting, B., Lyons, K. A., Scapin, G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070330v · Cited by 62
Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters
Durinx, C., Neels, H. M., der Auwera, J.-C. V., Naelaerts, K., Scharpé, S., & Meester, I. D. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.026 · Cited by 62
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
Hansen, M. S., Søe, K., Christensen, L. L., Fernandez-Guerra, P., Hansen, N. W., Wyatt, R. A., Martin, C., Hardy, R. S., Andersen, T. L., Olesen, J. B., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac004 · Cited by 62
Discovery, Structure−Activity Relationship, and Pharmacological Evaluation of (5-Substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as Potent Dipeptidyl Peptidase IV Inhibitors
Pei, Z., Li, X., Longenecker, K. L., von Geldern, T. W., Wiedeman, P. E., Lubben, T. H., Zinker, B. A., Stewart, K. D., Ballaron, S. J., Stashko, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051283e · Cited by 61
In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes
Soltani, N., Kumar, M., Glinka, Y., Prud’homme, G. J., & Wang, Q. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302944 · Cited by 61
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system
Pérez–Tilve, D., González-Matías, L. C., Aulinger, B. A., Álvarez-Crespo, M., Gil‐Lozano, M., Alvarez, E., Andrade-Olivie, A. M., Tschöp, M. H., D’Alessio, D. A., & Mallo, F. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00464.2009 · Cited by 62
In vivo and in vitro degradation of peptide YY3–36 to inactive peptide YY3–34 in humans
Toräng, S., Bojsen-Møller, K. N., Svane, M. S., Hartmann, B., ROSENKILDE, M. M., Madsbad, S., & Holst, J. J. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00394.2015 · Cited by 60
A synthetic glucagon-like peptide-1 analog with improved plasma stability
Ritzel, U., Leonhardt, U., Ottleben, M., Rühmann, A., Eckart, K., Spiess, J., & Ramadori, G. P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590093 · Cited by 61
Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance
Punjabi, M., Arnold, M., Rüttimann, E., Graber, M., Geary, N., Pacheco-López, G., & Langhans, W. (2014) · Endocrinology · doi:10.1210/en.2013-1447 · Cited by 59
The glucagon‐like peptide‐1 receptor binding site for the N‐terminus of GLP‐1 requires polarity at Asp198 rather than negative charge
de Maturana, R. L., & Donnelly, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03492-0 · Cited by 60
The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Adamska-Patruno, E., Ostrowska, L., Górska, M., & Kretowski, A. J. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.42498 · Cited by 60
GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines
Kuhre, R. E., Albrechtsen, N. J. W., Windeløv, J. A., Svendsen, B., Hartmann, B., & Holst, J. J. (2014) · Peptides · doi:10.1016/j.peptides.2014.01.020 · Cited by 60
Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences
Karl, T., Hoffmann, T., Pabst, R., & von Hörsten, S. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00229-4 · Cited by 60
The effect of yellow pea protein and fibre on short-term food intake, subjective appetite and glycaemic response in healthy young men
Smith, C. E., Mollard, R. C., Luhovyy, B. L., & Anderson, G. H. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000700 · Cited by 63
Comparative Effects of the Endogenous Agonist Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide and the Small-Molecule Ago-Allosteric Agent “Compound 2” at the GLP-1 Receptor
Coopman, K., Huang, Y., Johnston, N., Bradley, S. J., WILKINSON, G. F., & Willars, G. B. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166009 · Cited by 60
Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 61
Why is it so difficult to measure glucagon-like peptide-1 in a mouse?
Windeløv, J. A., Albrechtsen, N. J. W., Kuhre, R. E., Jepsen, S. L., Hornburg, D., Pedersen, J., Jensen, E. P., Galsgaard, K. D., Winther‐Sørensen, M., Ørgaard, A., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4347-7 · Cited by 61
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 59
Self-citation
Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells
Fujita, Y., Chui, J. W. Y., King, D., Zhang, T., Seufert, J., Pownall, S., Cheung, A. T., & Kieffer, T. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90440.2008 · Cited by 58
Self-citation
Preparation, Characterization, and Application of Biotinylated and Biotin−PEGylated Glucagon-Like Peptide-1 Analogues for Enhanced Oral Delivery
Chae, S. Y., Jin, C., Shin, H. J., Youn, Y. S., Lee, S., & Lee, K. C. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700292v · Cited by 59
Calorie Restriction and Matched Weight Loss From Exercise: Independent and Additive Effects on Glucoregulation and the Incretin System in Overweight Women and Men
Weiss, E. P., Albert, S. G., Reeds, D. N., Kress, K. S., Ezekiel, U. R., McDaniel, J. L., Patterson, B. W., Klein, S., & Villareal, D. T. (2015) · Diabetes Care · doi:10.2337/dc14-2913 · Cited by 61
Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
Deacon, C. F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.4.533 · Cited by 59
A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes
Irwin, N., Green, B. D., Mooney, M. H., Greer, B., Harriott, P., Bailey, C. J., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086082 · Cited by 59
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
McKillop, A. M., Duffy, N. A., Lindsay, J. R., O'Harte, F. P. M., Bell, P. M., & Flatt, P. R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.001 · Cited by 58
The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity
Doyle, M. E., Theodorakis, M. J., Holloway, H. W., Bernier, M., Greig, N. H., & Egan, J. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00120-4 · Cited by 58
Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats
Sokar, S. S., El‐Sayad, M. E., Ghoneim, M. E.-S., & Shebl, A. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.010 · Cited by 58
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)
Kim, D., Kowalchick, J. E., Edmondson, S. D., Mastracchio, A., Xu, J., Eiermann, G. J., Leiting, B., Wu, J. K., Pryor, K. D., Patel, R. A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.098 · Cited by 58
Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes
Augustyns, K., der Veken, P. V., Senten, K., & Haemers, A. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.499 · Cited by 58
Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Barchetta, I., Cimini, F. A., Dule, S., & Cavallo, M. G. (2022) · Biomedicines · doi:10.3390/biomedicines10092306 · Cited by 60
Renoprotection by pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney diseases
Li, M., Maderdrut, J. L., Lertora, J. J. L., Arimura, A., & Batuman, V. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.09.012 · Cited by 57
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Jespersen, M. J., Knop, F. K., & Christensen, M. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.731394 · Cited by 57
New-Onset Diabetes Mellitus in the Kidney Recipient
Bloom, R. D., & Crutchlow, M. F. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02650707 · Cited by 59
Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective
Deacon, C. F., & Holst, J. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00359-5 · Cited by 55
In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7–36) amide in the rat studied by gamma camera
Hassan, M., Eskilsson, A., Nilsson, C., Jonsson, C., Jacobsson, H., Refai, E., Larsson, S., & Efendić, S. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00121-8 · Cited by 58
Glucagon-like Peptide 2
Drucker, D. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00136-2 · Cited by 55
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., & Tanaka, I. (2003) · Metabolism · doi:10.1053/meta.2003.50014 · Cited by 55
Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
Duvnjak, L. S., & Blaslov, K. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0144-6 · Cited by 55
GPR119: “Double-Dipping” for Better Glycemic Control
Lauffer, L., Iakoubov, R., & Brubaker, P. L. (2008) · Endocrinology · doi:10.1210/en.2008-0182 · Cited by 55
Elevated Plasma Glucose-Dependent Insulinotropic Polypeptide Associates With Hyperinsulinemia in Impaired Glucose Tolerance
Theodorakis, M. J., Carlson, O. D., Muller, D. C., & Egan, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1692 · Cited by 56
Exploring structural features of potent dipeptidyl peptidase IV (DPP-IV) inhibitory peptides derived from tilapia (Oreochromis niloticus) skin gelatin by an integrated approach of multivariate analysis and Gly-Pro-based peptide library
Xu, Q., Zheng, L. P., Huang, M., & Zhao, M. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.133821 · Cited by 54
Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor
Kirkpatrick, A., Heo, J., Abrol, R., & Goddard, W. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218051109 · Cited by 53
The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
Barnett, A. H. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01523.x · Cited by 55
Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor
Miyamoto, Y., Banno, Y., Yamashita, T., Fujimoto, T., Oi, S., Moritoh, Y., Asakawa, T., Kataoka, O., Yashiro, H., Takeuchi, K., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101236h · Cited by 54
Discovery of ((4 R ,5 S )-5-Amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8 H )-yl)methanone (ABT-341), a Highly Potent, Selective, Orally Efficacious, and Safe Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Pei, Z., Li, X., von Geldern, T. W., Madar, D. J., Longenecker, K. L., Yong, H., Lubben, T. H., Stewart, K. D., Zinker, B. A., Backes, B. J., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060955d · Cited by 54
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus
McIntosh, C. H. S., Demuth, H., Kim, S.-J., Pospisilik, J. A., & Pederson, R. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.013 · Cited by 54
Self-citation
Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications
Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
Endocrine pancreatic insufficiency in chronic pancreatitis
Angelopoulos, N., Dervenis, C., Goula, A., Rombopoulos, G., Livadas, S., Kaltsas, D., Kaltzidou, V., & Tolis, G. (2005) · Pancreatology · doi:10.1159/000085264 · Cited by 53
Angiotensin Receptor Blockade Increases Pancreatic Insulin Secretion and Decreases Glucose Intolerance during Glucose Supplementation in a Model of Metabolic Syndrome
Rodríguez, R., Viscarra, J. A., Minas, J. N., Nakano, D., Nishiyama, A., & Ortiz, R. M. (2012) · Endocrinology · doi:10.1210/en.2011-1885 · Cited by 56
Synthesis, biological evaluation and structural determination of β-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors
Ahn, J. H., Shin, M. S., Jun, M. A., Jung, S. H., Kang, S. K., Kim, K. R., Rhee, S. D., Kang, N. S., Kim, S. Y., Sohn, S.-K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.111 · Cited by 53
GIP(Lys16PAL) and GIP(Lys37PAL): Novel Long-Acting Acylated Analogues of Glucose-Dependent Insulinotropic Polypeptide with Improved Antidiabetic Potential
Irwin, N., O'Harte, F. P. M., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., & Flatt, P. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0509997 · Cited by 52
Low-molecular fraction of wheat protein hydrolysate stimulates glucagon-like peptide-1 secretion in an enteroendocrine L cell line and improves glucose tolerance in rats
Kato, M., Nakanishi, T., Tani, T., & Tsuda, T. (2016) · Nutrition Research · doi:10.1016/j.nutres.2016.12.002 · Cited by 50
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats
Yasuda, N., Nagakura, T., Yamazaki, K., Inoue, T., & Tanaka, I. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01637-5 · Cited by 52
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome
Drucker, D. J. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00016 · Cited by 53
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Residues within the Transmembrane Domain of the Glucagon-Like Peptide-1 Receptor Involved in Ligand Binding and Receptor Activation: Modelling the Ligand-Bound Receptor
Coopman, K., Wallis, R., Robb, G. R., Brown, A., WILKINSON, G. F., Timms, D. A., & Willars, G. B. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1160 · Cited by 53
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury
Hirata, Y., Kurobe, H., Nishio, C., Tanaka, K., Fukuda, D., Uematsu, E., Nishimoto, S., Soeki, T., Harada, N., Sakaue, H., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.057 · Cited by 51
A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis
Cho, J. M., Jang, H. W., Cheon, H., Jeong, Y. T., Kim, D., Lim, Y.-M., Choi, S., Yang, E.-K., Shin, C.-Y., Son, M. H., et al. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.10.012 · Cited by 51
Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability and in Vivo Potency
ŠEBÖKOVÁ, E., Christ, A. D., Wang, H., Sewing, S., Dong, J. Z., Taylor, J., Cawthorne, M. A., & Culler, M. D. (2010) · Endocrinology · doi:10.1210/en.2009-1459 · Cited by 51
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
Therapeutic vaccine against DPP4 improves glucose metabolism in mice
Pang, Z., Nakagami, H., Osako, M. K., Koriyama, H., Nakagami, F., Tomioka, H., Shimamura, M., Kurinami, H., Takami, Y., Morishita, R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322009111 · Cited by 50
Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
Wang, Q., Chen, K., Liu, R., Zhao, F., Gupta, S., Zhang, N., & Prud’homme, G. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012734 · Cited by 50
Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.525 · Cited by 50
Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats
Karl, T., Chwalisz, W. T., Wedekind, D., Hedrich, H. J., Hoffmann, T., Jacobs, R., Pabst, R., & von Hörsten, S. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00149-6 · Cited by 50
Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice
Porter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 51
Effect of Aging and Diabetes on the Enteroinsular Axis
Korosi, J., McIntosh, C. H. S., Pederson, R. A., Demuth, H., Habener, J. F., Gingerich, R. L., Egan, J. M., Elahi, D., & Meneilly, G. S. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.9.m575 · Cited by 50
Self-citation
(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Biftu, T., Feng, D., Qian, X., Liang, G., Kieczykowski, G. R., Eiermann, G. J., He, H., Leiting, B., Lyons, K., Petrov, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.099 · Cited by 50

Authors: Kieffer, T. J., McIntosh, C. H., & Pederson, R. A.
Affiliations: University of British Columbia (CA)
ORCID: Kieffer, T J
Venue: Endocrinology
Publisher: The Endocrine Society
Published: 1995-08
Volume: 136
Issue: 8
Pages: 3585-3596
ISSN: 0013-7227 (ISSN-L)
1945-7170
DOI: 10.1210/endo.136.8.7628397
OpenAlex: W1978953702
Cited by: 1,124
References: 36
Citations by year: 2026: 9 · 2025: 31 · 2024: 30 · 2023: 15 · 2022: 27 · 2021: 36 · 2020: 23 · 2019: 37 · 2018: 25 · 2017: 40 · 2016: 39 · 2015: 54 · 2014: 47 · 2013: 53 · 2012: 61
FWCI: 6.60
Type: journal article
Language: en
Open access: closed
Locations: Endocrinology (publishedVersion)
PubMed (publishedVersion)
Funders: Massachusetts General Hospital
Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dipeptidyl peptidase IV, hormone degradation, incretin effect, N-terminal truncation, diprotin A, radiolabeled peptides, insulin secretion, circulating hormone levels
MeSH terms: Animals, Blood Physiological Phenomena, Glucagon-Like Peptides, Glucagon, Glucose, Peptide Fragments, Peptides, Protein Precursors, Rats, Inbred F344, Rats, Wistar, Dipeptidyl Peptidase 4, Rats, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks